Pharmacokinetic herb-drug interactions: Are preventive screenings necessary and appropriate?

Planta Medica

Volumn 70, Issue 9, 2004, Pages 784-791

  Butterweck, Veronika ^a   Derendorf, Hartmut ^a   Gaus, Wilhelm ^b   Nahrstedt, Adolf ^c   Schulz, Volker ^d   Unger, Matthias ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b Abt Biometrie/Med Dokumentation   (Germany)

^c Inst Pharmaceutical Biol P   (Germany)

^d Institut für Pharmazie ^*  (Germany)

Author keywords

Cytochrome P450; Food drug interactions; Herb drug interactions; P glycoprotein; Pharmacokinetic drug interactions; Preventive screenings

Indexed keywords

CARRIER PROTEIN; CYTOCHROME P450 ISOENZYME; DRUG; ENZYME; GLYCOPROTEIN P; HERBACEOUS AGENT; NATURAL PRODUCT;

BEVERAGE; CLINICAL STUDY; DIET; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; FOOD DRUG INTERACTION; HERBAL MEDICINE; IN VITRO STUDY; LIFESTYLE; MEDICAL DECISION MAKING; PHARMACOKINETICS; REVIEW; RISK ASSESSMENT; SCREENING; THERAPEUTIC INDEX; VALIDATION PROCESS;

CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

ANIMALIA;

EID: 5444249742     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-827223     Document Type: Review

References (68)

1. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, Bent S, Boon H, Ernst E. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44: 271-82
2. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56
3. Schulz V, Johne A. Side effects and drug interactions. In: Müller WE, ed. St. John's Wort and its active principles in depression and anxiety. Milestones in Drug Therapy Basel, Switzerland: Birkhäuser, 2004
4. Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion 2000; 13: 4-15
5. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163-75
6. Boon H, Jurgens T. Drug Interactions with Natural Health Products: A Discussion Paper. Health Canada Website, 2002
7. Hohl K, Gaus W. Bibliography on interactions between drugs and herbs and between drugs and food-supplements. 2004 http://www.u-ni-ulm.de/uni/fak/medizin/ biodok/v4/herb_drug_interactions.html,
8. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 2003; 42: 153-78
9. Limon L. Drug interactions. Decreasing the risk. American Pharmaceutical Association Annual Meeting, Washington, DC: 2000
10. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate and tissue distribution of cytochrome P450 and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995; 13: 129-34
11. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993; 24: 77-97
12. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 246-80
13. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-62
14. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003; 42: 1071-88
15. Kivisto KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66: 448-53
16. Estabrook RW. A passion for P450 s (remembrances of the early history of research on cytochrome P450). Drug Metab Dispos 2003; 31: 1461-73
17. Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8: 293-308
18. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10: 334-42
19. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11: 98-104
20. Lampen A. Interaktion zwischen Metabolismus und Transport von toxisch relevanten Substanzen in der gastrointestinalen Barriere. Biospektrum 2004; 10: 157-9
21. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001; 70: 462-7
22. Unger M. Wie Naturstoffe die Bioverfuegbarkeit von Arzneistoffen beeinflussen. Pharm Ztg 2004; 149: 979-86
23. U.S. Food Administration A. Guidance for industry: Drug metabolism/Drug interaction studies in the drug development process: Studies in vitro. Rockville, MD: 1997 http://www.fda.gov/cber/cberftp.html,
24. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89-100
25. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-8
26. Zou L, Harkey MR, Henderson GL. Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products. Phytomedicine 2002; 9: 263-7
27. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29: 30-5
28. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-82
29. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95
30. BfArM. Bewertung möglicher pharmakokinetischer Arzneimittel- Interaktionen mit Phytopharmaka (Entwurf). 2004 www.bfarm.de/de/Arzneimittel/ bes_therap/am_pflanzl/int_20040116.pdf.
31. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 1999; 45: 91-8
32. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002; 6:189-98
33. Derendorf H, Hochhaus G. Handbook of Pharmacokinetic-Pharmacodynamic Correlations. Boca Raton, Florida: 1995: 483
34. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concenpts and perspectives. Pharm Res 1999; 16: 176-85
35. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-69
36. Huang SM. Issues and challenges in the evaluation and labeling of drug interaction potentials of NME FDA Clinical Pharmacology Subcommittee Advisory Board Meeting. Washington DC: 2003
37. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128: 281-5
38. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9: 301-9
39. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 2004; 164: 630-6
40. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-44
41. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 1A2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv Exp Med Biol 1991; 283: 407-11
42. Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, Feng Z, Potter JD. Brassica vegetables increase and apiaceous vegetables decrease cytochrome 450 1A2 activity in humans: changes in caffeine metabolite esponse to controlled vegetable diets. Carcinogenesis 2000; 21: 1157-62
43. Jeppesen U, Loft S, Poulsen HE, Brsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6: 213-22
44. Monks TJ, Caldwell J, Smith RL. Influence of methylxanthine-containing foods on theophylline metabolism and kinetics. Clin Pharmacol Ther 1979; 26: 513-24
45. Cone EJ, Fant RV, Henningfield JE. Nicotine and Tobacco. In: Mozayani A, Raymond LP, eds. Handbook of Drug Interactions Totova, New Jersey: Humana Press, 2004: 463-92
46. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
47. Bailey DG, Malcolm AO, Munoz C, Spence JD. Grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54: 589-94
48. Soons PA, Vogels BA, Roosenmalen MC, Shoemaker HC, Uchida E, Edgar B, Lundahl Cohen AF, Bremer DD. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50: 393-403
49. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentration of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9
50. Westveer MK, Farquhar ML, George P, Mayers JT. Co-administration of grapefruit juice increases tacrolimus levels in liver transplant recipients. Ann Meet Am Soc Transplant Physicians 1996; 202: 115
51. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in human. Clin Pharmacol Ther 1995; 58: 20-8
52. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127-31
53. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-8
54. Ozdemir M, Atkan Y, Boydag BS, Cibgi MI, Musmul A. Interaction between grapefruit jucie and diazepam in human. Eur J Drug Metab Pharmacokin 1998; 23: 55-9
55. Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-9
56. Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matth K. Can grapefruit juice influence ethinylestradiol bioavailability. Contraception 1996; 53: 41-7
57. Fuhr U, Klittch K, Atab AH. Inhibitory effect of grapefruit juice and its bitter principle, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35: 431-6
58. Simopoulos AP, Kifer RR, Martin RE. Health effects of polyunsaturated fatty acids in seafoods. Orlando, San Diego, New York: Academic Press Inc, 1986: 383-401
59. Conney AH, Pantuck EJ, Hsiao KC, Garland WA, Anderson KE, Alvares AP, Kappas A. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20: 633-42
60. Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 88-95
61. Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A. Effect of Brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther 1984; 35: 161-9
62. Pantuck EJ, Pantuck CB, Anderson KE, Conney AH, Kappas A. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 1982; 31: 533-8
63. Bailey DG, Arnold JM, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-42
64. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′- dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64: 248-56
65. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47: 1503-8
66. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 1996; 17: 793-9
67. Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998; 64: 144-9
68. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69: 14-23